Why Pfizer Fell Short in Q4
Pfizer Inc. (NYSE: PFE) released its fourth-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $0.64 in earnings per share (EPS) and $14.0 ...Read Full Story »
Healthcare Business - Page 2
Read Full Story »
What to Expect When Pfizer Reports Tuesday
Pfizer Inc. (NYSE: PFE) is scheduled to release its fourth-quarter financial results before the markets open on Tuesday. Consensus analyst estimates call for $0.64 in earnings per share (EPS) and ...Read Full Story »
Short Interest Spikes in a Couple Major Pharma Stocks
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...Read Full Story »
Short Sellers Back Off Major Biotechs
The short interest data are out for the most recent settlement date, January 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...Read Full Story »
How AbbVie Tripped Up in Q4
When AbbVie Inc. (NYSE: ABBV) released its fourth-quarter financial results before the markets opened on Friday, the pharmaceutical giant said that it had $1.90 in earnings per share (EPS) and ...Read Full Story »
Why the Bristol-Myers Incredible Earnings Beat Is Getting Grounded
When Bristol-Myers Squibb Co. (NYSE: BMY) reported its most recent quarterly results before the markets opened on Thursday, the company said that it had $0.94 in earnings per share (EPS) ...Read Full Story »
Can Editas Survive After Losing Its CEO?
Editas Medicine Inc. (NASDAQ: EDIT) shares were crushed on Tuesday after the company announced that its president and chief executive, Katrine Bosley, would be stepping down from these roles effective ...Read Full Story »
Johnson & Johnson Earnings: When Good Enough Just Isn’t Good Enough
Johnson & Johnson (NYSE: JNJ) released its fourth-quarter financial results before the markets opened on Tuesday. The health care giant said that it had in $1.97 earnings per share (EPS) ...Read Full Story »
FDA Diabetes Treatment Vote to Determine the Fate of Lexicon Therapeutics?
Lexicon Pharmaceutics Inc. (NASDAQ: LXRX) shares fell on Friday after the U.S. Food and Drug Administration (FDA) voted to approve the firm’s type 1 diabetes treatment. Although the result from ...Read Full Story »
Is Immunomedics Breast Cancer Treatment Doomed After This FDA Update?
Immunomedics Inc. (NASDAQ: IMMU) shares were crushed on Friday after the firm received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Usually, CRLs can spell ...Read Full Story »
Is Spectrum Pharma Getting Enough for Its Hematology/Oncology Portfolio?
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares made a handy gain early Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech ...Read Full Story »
Where Does Aptinyx Go Next After Disappointing Midstage Results for Pain Treatment?
Aptinyx Inc. (NASDAQ: APTX) shares were absolutely crushed on Wednesday after the firm reported midstage results from its clinical study in patients with painful diabetic peripheral neuropathy (DPN). Specifically, Aptinyx ...Read Full Story »
Why CVS and Walmart Are Parting Ways
CVS Health Corp. (NYSE: CVS) has announced that it will be parting ways with megastore Walmart Inc. (NYSE: WMT). Specifically, Walmart has opted to leave the CVS Caremark pharmacy benefit management ...Read Full Story »
Major Pharma Sees Fading Short Interest
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...Read Full Story »
Major Biotechs Scare Off Short Sellers
The short interest data are out for the most recent settlement date, December 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...Read Full Story »
-
Categories
- Aerospace & Defense (1,300)
- Apps & Software (863)
- Array (2)
- Autos (3,829)
- Banking & Finance (4,616)
- Casinos & Hotels (227)
- Commodities & Metals (1,787)
- Consumer Products (2,194)
- Economy (4,314)
- Energy Business (5,418)
- Energy Economy (1,640)
- General (31)
- Healthcare Business (4,034)
- Healthcare Economy (350)
- Housing (2,489)
- Industrials (1,001)
- Infrastructure (455)
- Investing (29,834)
- Jobs (1,143)
- Media (5,879)
- Retail (4,929)
- Services (1,262)
- Special Report (3,004)
- Sponsored Content (2)
- Technology (6,423)
- Telecom & Wireless (2,154)
- Transportation (803)
